Amine Benmassaoud1, Talal Al-Taweel1,2, Mark Solomon Sasson1, Dasha Moza1, Matthew Strohl1, Uri Kopylov1,3, Laurence Paradis-Surprenant1, Mohanad Almaimani1, Alain Bitton1, Waqqas Afif1, Peter L Lakatos1,4, Talat Bessissow5. 1. Division of Gastroenterology, Montreal General Hospital, McGill University Health Center, 1650, Cedar Avenue, C7-200, Montreal, QC, H3G 1A4, Canada. 2. Haya Al-Habeeb Gastroenterology Center, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait. 3. Department of Gastroenterology, Sheba Medical Centre, Tel-Aviv, Israel. 4. First Department of Medicine, Semmelweis University, Budapest, Hungary. 5. Division of Gastroenterology, Montreal General Hospital, McGill University Health Center, 1650, Cedar Avenue, C7-200, Montreal, QC, H3G 1A4, Canada. talat.bessissow@mcgill.ca.
Abstract
BACKGROUND: Direct head-to-head studies comparing the long-term outcomes of infliximab (IFX) to adalimumab (ADA) in Crohn's disease (CD) are sparse. AIMS: We compared the short-term and long-term efficacy and safety of IFX and ADA in CD. METHODS: We performed a single-center retrospective study including biologic-naïve adult patients with CD who were started on IFX or ADA at the McGill University Health Center. The primary end points were clinical response and remission at 12 months. Secondary end points included corticosteroid-free remission at 12 months, durable remission, and treatment failure with need for steroids, hospitalization or surgery. Safety was also assessed. RESULTS: Two hundred and twenty patients were included (143 IFX, 77 ADA). Patients on IFX had a higher prevalence of fistulizing or perianal disease and corticosteroid treatment at baseline. Rates of clinical remission and corticosteroid-free remission at 12 months were similar between both groups: 63.8 versus 76.3% (p = 0.139) and 54.1 versus 44.7% (p = 0.354), respectively, for IFX and ADA. Combination therapy led to significantly higher remission rates at 12 months compared to monotherapy for patients on IFX (81.2 vs. 52.1%, p = 0.008), but not for those on ADA. Higher rates of adverse events were reported with IFX compared to ADA (p = 0.006). CONCLUSIONS: Our real-life experience in biologic-naïve CD patients demonstrated that patients started on IFX were more likely to have a harder-to-treat phenotype. Despite that, efficacy end points were similar between both groups. Clinical remission was higher in patients with combination therapy for IFX, but not for those on ADA. This warrants further investigation.
BACKGROUND: Direct head-to-head studies comparing the long-term outcomes of infliximab (IFX) to adalimumab (ADA) in Crohn's disease (CD) are sparse. AIMS: We compared the short-term and long-term efficacy and safety of IFX and ADA in CD. METHODS: We performed a single-center retrospective study including biologic-naïve adult patients with CD who were started on IFX or ADA at the McGill University Health Center. The primary end points were clinical response and remission at 12 months. Secondary end points included corticosteroid-free remission at 12 months, durable remission, and treatment failure with need for steroids, hospitalization or surgery. Safety was also assessed. RESULTS: Two hundred and twenty patients were included (143 IFX, 77 ADA). Patients on IFX had a higher prevalence of fistulizing or perianal disease and corticosteroid treatment at baseline. Rates of clinical remission and corticosteroid-free remission at 12 months were similar between both groups: 63.8 versus 76.3% (p = 0.139) and 54.1 versus 44.7% (p = 0.354), respectively, for IFX and ADA. Combination therapy led to significantly higher remission rates at 12 months compared to monotherapy for patients on IFX (81.2 vs. 52.1%, p = 0.008), but not for those on ADA. Higher rates of adverse events were reported with IFX compared to ADA (p = 0.006). CONCLUSIONS: Our real-life experience in biologic-naïve CDpatients demonstrated that patients started on IFX were more likely to have a harder-to-treat phenotype. Despite that, efficacy end points were similar between both groups. Clinical remission was higher in patients with combination therapy for IFX, but not for those on ADA. This warrants further investigation.
Authors: Uri Kopylov; Talal Al-Taweel; Mohammad Yaghoobi; Benedicte Nauche; Alain Bitton; Peter L Lakatos; Shomron Ben-Horin; Waqqas Afif; Ernest G Seidman Journal: J Crohns Colitis Date: 2014-07-25 Impact factor: 9.071
Authors: A Cholapranee; G S Hazlewood; G G Kaplan; L Peyrin-Biroulet; A N Ananthakrishnan Journal: Aliment Pharmacol Ther Date: 2017-03-22 Impact factor: 8.171
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: W J Sandborn; S B Hanauer; P Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; R Panaccione; D Wolf; J D Kent; B Bittle; J Li; P F Pollack Journal: Gut Date: 2007-02-13 Impact factor: 23.059
Authors: Christine Kestens; Martijn G H van Oijen; Charlotte L J Mulder; Ad A van Bodegraven; Gerard Dijkstra; Dirk de Jong; Cyriel Ponsioen; Bas A C van Tuyl; Peter D Siersema; Herma H Fidder; Bas Oldenburg Journal: Clin Gastroenterol Hepatol Date: 2013-01-29 Impact factor: 11.382
Authors: Christopher Ma; Vivian Huang; Darryl K Fedorak; Karen I Kroeker; Levinus A Dieleman; Brendan P Halloran; Richard N Fedorak Journal: J Crohns Colitis Date: 2014-06-16 Impact factor: 9.071
Authors: Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack Journal: Gastroenterology Date: 2006-02 Impact factor: 22.682